CanVECTOR aims to advance VTE prevention, diagnosis, and treatment through clinical, basic, translational, and population research. By developing shared platforms and conducting pilot trials, we enhance efficiency and reduce duplication to better secure large-scale funding for collaborative studies. We support high-impact research through funding for pilot studies, trainees, and capacity-building initiatives, including our Clinical Investigation Group (CIG).